tagitanlimab

Overview

Tagitanlimab is an investigational anti-PD-L1 monoclonal antibody targeting CD274. It is evaluated in combination with chemotherapy for recurrent/metastatic nasopharyngeal carcinoma (NPC).

Evidence in the corpus

• Phase III tagitanlimab + gemcitabine/cisplatin in R/M NPC (NCT05294172, n=358): PFS HR 0.47; ORR 81.7%; median DOR 11.7 months; grade ≥3 TRAE 3.9% PMID:24952746.

Resistance mechanisms

Cancer types (linked)

• NPC

Sources

This page was processed by entity-page-writer on 2026-05-11.